Editas Medicine (EDIT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist

2.200
-0.010-0.45%

Close Nov 27 16:00 ET

2.201
+0.001+0.05%

Post 16:25 ET

181.61MMarket Cap-866P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Bank of America Securities Downgrades Editas Medicine (EDIT) to a Sell
TipRanksNov 25 09:55 ET · Ratings
BofA Securities Downgrades Editas Medicine to Underperform
MT NewswiresNov 25 07:51 ET
Express News | Editas Medicine Inc : BofA Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $13
ReutersNov 25 06:06 ET
Revenues Working Against Editas Medicine, Inc.'s (NASDAQ:EDIT) Share Price Following 34% Dive
Simply Wall StNov 20 05:24 ET
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Earnings Call TranscriptsNov 19 19:53 ET
Insider Sellers Might Regret Selling Editas Medicine Shares at a Lower Price Than Current Market Value
Simply Wall StNov 18 06:26 ET

Comments

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...

wompwomp1337

Sep 6 06:09

$Editas Medicine (EDIT.US)$ seems like Feng Zhang and his team are making leeway with the ultra selfish gene

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

Jaguar8

May 10 05:01

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

Investment Theme

Gene Editing

Intraday+0.56%

EDIT Editas Medicine

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target